New Report Available: Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019

Chronic lymphocytic leukemia is a malignant condition characterized by increased production of lymphocytes. It has been observed that the cancer first affects B-lymphocytes and then it can spread to other parts of the body. This leukemia is diagnosed mostly at later stages because of the slow buildup of the cancerous cells. During the course of the disease, the malignancy spreads to the spleen, liver, and lymph nodes. The course of the disease is heterogeneous, and prognosis is difficult. Symptoms include swelling of the lymph nodes, fatigue, fever, infection, pain beneath the ribs, and weight loss. Chronic lymphocytic leukemia can be treated with radiation, steroids, chemotherapy, targeted therapy, transplants (bone marrow, stem cell), and surgical procedure to remove the spleen (splenectomy).

Technavio's analysts forecast the global chronic lymphocytic leukemia therapeutics market to grow at a CAGR of 18.52% over the period 2014-2019.

Commenting on the report, an analyst from Technavio's team said: "Vendors are increasingly forming strategic alliances to increase their market shares. Co-development agreements allow the sharing of regulatory and developmental experiences gained by either company to support pipeline candidates."

According to the report, "The increase in the patient pool for chronic lymphocytic leukemia is a major driver of the market. The elderly are more likely to be diagnosed with chronic lymphocytic leukemia. The older adult population is increasing globally, which indicates that the probability of getting chronic lymphocytic leukemia is also rising. As a result, the consumption of medications will increase, which will generate substantial revenue in the market."

Further, the report states that the unknown etiology of chronic lymphocytic leukemia is a major challenge because vendors are unable to target the basic cause of the disease. This makes it difficult for them to develop a drug that can effectively treat and cure the disease.

The key players in the Global Chronic Lymphocytic Leukemia Therapeutics Market are F. Hoffmann-La Roche, Novartis and Teva Pharmaceutical Industries while other prominent vendors include Actavis, Amgen, Aryogen, Astellas, Bristol-Myers Squibb, Eagle Pharmaceuticals, Eisai, Fresenius Kabi, Genmab, Gilead Sciences, H. Lundbeck, Hospira, idd biotech, Immunomedics, Johnson & Johnson, Mundipharma, Mylan, Noxxon and Ono Pharmaceutical.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014
- Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014
- B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2015
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
- Chronic Urticaria Or Hives Global Clinical Trials Review, H1, 2015